Global Breast Cancer Screening Tests Market - Industry Analysis and Market Forecast (2017 - 2022)

Breast cancer screening is carried out to detect cancer in its early stages, and ensure timely treatment of the patients. The American Cancer Society states that breast cancer is the most common cancer among women, accounting for more than 1 in 8 cancers diagnosed in American women. There are different types of breast cancer depending on the type of breast cell that becomes cancerous. Breast cancer can affect different parts of the breast, such as the ducts and the lobes. The breast cancer screening tests market for the United States was estimated to be USD XX billion in 2015 and is expected to grow ten times during the decade.

Although mammography is usually the first step of breast cancer screening, molecular testing is gaining attention as the first step of the screening process. Therefore, the market for molecular testing is forecasted to grow at a strong CAGR.

The major factors that contribute to the risk of breast cancer include gender, age and family history regarding breast cancer. There have been a number of initiatives to increase awareness about breast cancer screening and the benefits of early diagnosis of the disease. A lot of innovation and research is going on regarding breast cancer screening, which is a driver for this market.

The report is segmented based on the type of tests (blood marker tests, fluorescence in situ hybridization, immunohistochemistry, MammaPrint test and mammogram) and by geography (Asia-Pacific, Europe, North America & South America).

The number of cases of breast cancer is the highest in North America, followed by Western Europe, Australia and the rest of Europe. With the availability of early screening procedures and reimbursements, North America has the largest market share, followed by Europe. Asia-Pacific is the fastest growing market as there is an increase in awareness and large government and private investments in research and development for breast cancer screening in this region. Mammograms are the most widely used techniques for breast cancer screening, while blood tests and other imaging techniques are now becoming popular.

Some of the key players in the market are:

A&G Pharmaceutical, Inc.

Biocrates Life Sciences AG

Metabolomic Technologies Inc.

Myriad Genetics

Panacea Pharmaceuticals, Inc.

Siemens Healthcare Diagnostics Inc.

Key Deliverables in the Study

Market analysis for the breast cancer screening tests market, with region-specific assessments and competition analysis on the global and regional scale.

Market definition along with the identification of key drivers and restraints.

Identification of factors instrumental in changing the market scenario, rising prospective opportunities, and identification of key companies that can influence this market on a global and regional scale.

Extensively researched competitive landscape section with profiles of major companies along with their market share.

Identification and analysis of the macro and micro factors that affect the market on both global and regional scale.

A comprehensive list of key market players along with the analysis of their current strategic interests and key financial information.

A wide-ranging knowledge and insights about the major players in this industry and the key strategies adopted by them to sustain and grow in the studied market.

Insights on the major countries/regions where this industry is blooming and to also identify the regions that are still untapped.

1 Introduction

1.1 Report Description

1.2 Research Methodology

2 Breast Cancer Screening Tests Market Overview

2.1 Breast Cancer Screening Tests Regulatory Framework

2.1.1 Europe Regulation

2.1.2 United States Regulation

2.1.3 Regulations in Other Countries

3 Global Breast Cancer Screening Tests - Market Forces

3.1 Market Drivers

3.1.1 Increase of Pipeline Breast Cancer Screening Tests

3.1.2 Adoption of Highly Effective Tests

3.1.3 Increasing Consumer Awareness

3.2 Market Restraints

3.2.1 Screening Tests Cost

3.2.2 Reimbursement

3.2.3 Economic Uncertainty

3.3 Market Opportunities

3.3.1 New Tests and Approaches in Development

3.4 Market Threats

3.5 PorterFive Forces

3.5.1 Bargaining Power of Suppliers

3.5.2 Bargaining Power of Consumers

3.5.3 Threat of New Entrants

3.5.4 Threat of Substitute Products and Services

3.5.5 Competitive Rivalry within the Industry

4. Market Segmentation

4.1 Breast Cancer Screening Market Segmentation, By Tests

4.1.1 Blood Marker Tests

4.1.2 Fluorescence In Situ Hybridization (FISH) Tests

4.1.3 Immunohistochemistry (IHC) Tests

4.1.4 MammaPrint Test

4.1.5 Mammograms

4.1.6 Ultrasound

4.1.7 MRI

4.2 Market Segmentation by Geography

4.2.1 North America Breast Cancer Screening Tests Market, 2014-2020 United States Canada Mexico

4.2.2 Europe Breast Cancer Screening Tests Market, 2014-2020 France Germany Italy Spain United Kingdom Scandinavia BENELUX

4.2.3 Asia-Pacific Breast Cancer Screening Tests Market, 2014-2020 China India Japan South Korea Australia & New Zealand

4.2.4 Middle East & Africa GCC South Africa Others

4.2.5 South America Argentina Brazil Others

5. Competitive Landscape

5.1 New Product Innovations

5.2 Agreements, Partnerships, Joint Ventures and Collaborations

5.3 Mergers & Acquisitions

6 Company Profiles

6.1 A&G Pharmaceutical, Inc.

6.2 Abcodia Ltd.

6.3 Agendia BV

6.4 Armune BioScience, Inc.

6.5 Biocrates Life Sciences AG

6.6 BioMark Technologies Inc.

6.7 Chronix Biomedical, Inc.

6.8 Genomic Health, Inc.

6.9 Myriad Genetics

6.10 Insight Genetics, Inc.

6.11 Metabolomic Technologies Inc.

6.12 Nuclea Biotechnologies Inc.

6.13 Siemens Healthcare Diagnostics Inc.

6.14 Panacea Pharmaceuticals, Inc.

6.15 Quest Diagnostics Incorporated

6.16 Roche Diagnostics Limited

6.17 HTC Molecular Diagnostics Inc.

7 Appendix

7.1 Abbreviations

7.2 Sources

7.3 Bibliography

7.4 Disclaimer

Content are not available

Choose License Type